A biomimetic nanotherapeutic (MCM@MOF@irisin) has been proposed to effectively mitigate acute kidney injury by enhancing the targeted delivery of irisin, a type I membrane protein secreted by skeletal muscle in response to physical activity. The gene discussed is FNDC5; the disease is acute kidney injury.